Patents Assigned to Visgenx, Inc.
  • ELOVL2 constructs for human gene therapy
    Patent number: 11793890
    Abstract: Disclosed herein are therapeutic agents capable of increasing the expression level of ELOVL2. Also described herein are therapeutic agents that reduce or slow an aging phenotype. Methods for treating age-related eye diseases or conditions are also provided. Methods for treating an age-related eye disease or condition in a subject by administering one or more therapeutic agents are provided.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 24, 2023
    Assignee: Visgenx, Inc.
    Inventors: Christopher Chavez, Martin Emanuele